Viral Gene Therapy 2011
DOI: 10.5772/20568
|View full text |Cite
|
Sign up to set email alerts
|

Surface Modification of Retroviral Vectors for Gene Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
4

Relationship

3
1

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 149 publications
(190 reference statements)
0
5
0
Order By: Relevance
“…In this study, we could demonstrate that modification of retroviral vector particles with a regulator of the complement system using MP leaves them less susceptible to complement attack. On a more general note, this provides further evidence for the usefulness of MP in a range of biomedical applications, from labelling of virus particles for research purposes [ 26 ] and vaccination strategies using VLPs [ 32 , 34 ] to fine-tuning vector properties for gene therapy applications [ 25 , 27 , 28 , 30 ].…”
Section: Discussionmentioning
confidence: 99%
“…In this study, we could demonstrate that modification of retroviral vector particles with a regulator of the complement system using MP leaves them less susceptible to complement attack. On a more general note, this provides further evidence for the usefulness of MP in a range of biomedical applications, from labelling of virus particles for research purposes [ 26 ] and vaccination strategies using VLPs [ 32 , 34 ] to fine-tuning vector properties for gene therapy applications [ 25 , 27 , 28 , 30 ].…”
Section: Discussionmentioning
confidence: 99%
“…The most often used method is pseudotyping with proteins of heterologous viral origin [1, 35] or the use of fusion proteins consisting of mixed viral/nonviral sequences [1, 36, 37]. These require the activity of the cellular expression machinery [1]. In contrast, postexit procedures fall roughly into three categories: (i) direct covalent modification, (ii) the use of membrane-topic moieties, and (iii) the use of adaptor systems (see Figure 1 and Table 1 for an overview).…”
Section: Methodology: How Can R/lv Surfaces Be Modified After Theimentioning
confidence: 99%
“…While this inherent biocompatibility is at least partially responsible for their success, nevertheless a more controlled environment at the surface of R/LV particles would be beneficial for both, simplifying the regulatory/manufacturing aspects of gene therapy approaches as well as enhancing efficacy and safety of such approaches. More specifically, possibilities may be found in several areas: (i) easy concentration and purification of vector stocks for clinical use, (ii) being able to monitor administration and distribution of vectors (both of which can be achieved by suitable labeling), (iii) navigating the host response, especially a patient's immune response, and (iv) targeting of vectors to specific organs, tissues, or cell types (for a more extensive discussion see [1] and see also Figure 1 for an overview). …”
Section: Introduction: Why Modify Retroviral Surfaces?mentioning
confidence: 99%
“…Also, two independent GPI-APs (CD59 and GFP) could be associated with a lentiviral vector simultaneously ( 18 ). While these approaches were mostly targeted at facilitating gene therapy using VVs ( 18 , 29 , 55 , 89 , 90 ), recently strategies for the use in vaccination were suggested ( 19 , 36 , 51 , 91 , 92 ). In these studies, influenza VLPs were generated in a recombinant baculovirus system ( 93 , 94 ) and modified, on one hand, with either GPI-anchored IL12, GM-CSF, or ICAM-1 (collectively termed GPI immunostimulatory molecules) as adjuvant agents in anti-viral immune responses ( 19 ) and, on the other hand, with GPI-HER2 as a model for protein transfer of a tumor-associated antigen for tumor vaccination ( 36 ).…”
Section: Modification Of Virus Particlesmentioning
confidence: 99%